Manager × security

ARMISTICE CAPITAL, LLC NBIX holdings history

Who else holds this security? →

NEUROCRINE BIOSCIENCES INC · CUSIP 64125C109 · CIK 1601086

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, ARMISTICE CAPITAL, LLC reported 535.84K NBIX (shares), valued at $90.31M, or 2.50% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
2.50%
Shares
535.84K
535,838
Reported value
$90.31M
USD

Shares decreased 25.99%; reported value decreased 5.32%, and weight changed -0.65 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20262.50%535,838SEC filing ↗Filed Aug 14, 2026
Q1 20263.15%724,000SEC filing ↗Filed May 15, 2026
Q4 20252.85%820,240SEC filing ↗Filed Feb 17, 2026
Q3 20253.07%697,022SEC filing ↗Filed Nov 17, 2025
Q2 20253.22%676,024SEC filing ↗Filed Aug 14, 2025
Q1 20252.96%1,000,190SEC filing ↗Filed May 15, 2025
Q4 20242.83%892,000SEC filing ↗Filed Feb 14, 2025
Q3 20240.55%181,381SEC filing ↗Filed Nov 14, 2024
Q2 20243.52%978,488SEC filing ↗Filed Aug 14, 2024
Q1 20243.76%1,023,739SEC filing ↗Filed May 15, 2024
Q4 20233.67%1,048,000SEC filing ↗Filed Feb 13, 2024
Q3 20234.07%1,216,365SEC filing ↗Filed Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20234.07%1,216,365$136.84MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 14, 2023
Q4 20233.67%1,048,000$138.08MShares decreased 13.84%; reported value increased 0.91%, and weight changed -0.40 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 13, 2024
Q1 20243.76%1,023,739$141.19MShares decreased 2.31%; reported value increased 2.25%, and weight changed +0.09 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20243.52%978,488$134.71MShares decreased 4.42%; reported value decreased 4.59%, and weight changed -0.24 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20240.55%181,381$20.90MShares decreased 81.46%; reported value decreased 84.49%, and weight changed -2.97 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20242.83%892,000$121.76MShares increased 391.78%; reported value increased 482.61%, and weight changed +2.28 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20252.96%1,000,190$110.62MShares increased 12.13%; reported value decreased 9.15%, and weight changed +0.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20253.22%676,024$84.97MShares decreased 32.41%; reported value decreased 23.19%, and weight changed +0.26 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20253.07%697,022$97.85MShares increased 3.11%; reported value increased 15.16%, and weight changed -0.15 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 17, 2025
Q4 20252.85%820,240$116.33MShares increased 17.68%; reported value increased 18.89%, and weight changed -0.22 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20263.15%724,000$95.38MShares decreased 11.73%; reported value decreased 18.01%, and weight changed +0.30 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20262.50%535,838$90.31MShares decreased 25.99%; reported value decreased 5.32%, and weight changed -0.65 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
ARMISTICE CAPITAL, LLC · NEUROCRINE BIOSCIENCES INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1601086","quarter":"2026Q2","cusip":"64125C109"}

get_institutional_manager_history
{"cik":"1601086","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.